Suppression of PDLIM2 in invasive PRAD (DU145) and breast cancer cells (MDA-MB-231) causes increased E-cadherin expression and cell–cell contact, loss of directional migration, altered expression and activity of many transcription factors associated with tumorigenesis, and reversal of EMT [50]. Here, PDLIM2 is linked to breast cancer.